*April 2021*
NOTE: In a small percentage of EGFR+ lung cancer patients, transformation to SCLC can occur, perhaps as a resistance mechanism. Oncologists tend to treat SCLC transformation the same as de novo SCLC, but sometimes osimertinib is continued along with SCLC treatment. This article refers to de novo SCLC treatments, not transformed SCLC.
Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.
